Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

202
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
202
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

349
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
349
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperoxia reflects poor native cardiac function and demonstrates cardiac index-dependent associations with mortality in VA-ECMO patients.

European heart journal. Acute cardiovascular care·2026
Same author

Targeting JAK/STAT With Ruxolitinib in Acute Fulminant Myocarditis.

Journal of cardiac failure·2026
Same author

A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.

Cancer research communications·2026
Same author

Innate and Adaptive Immune Mechanisms in Pericarditis: Pathobiology and Clinical Implications.

The Canadian journal of cardiology·2026
Same author

Systemic hypoxia suppresses solid tumor growth.

bioRxiv : the preprint server for biology·2026
Same author

Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude.

Cell metabolism·2026

Related Experiment Video

Updated: Jan 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

Statin Use in Patients With Cancer: Drug Interaction and Statin Usage.

Emily Chou1, Carlo S Legasto2, Alan K Chin2

  • 1Department of Medicine, University of California Irvine Medical Center, Orange, California, USA.

JACC. Advances
|October 22, 2025
PubMed
Summary

Drug interactions between statins and cancer therapies are common, with most requiring monitoring rather than contraindication. Statin use varies by cancer type, necessitating personalized risk assessments for patients.

Keywords:
cancer survivorshipcardiotoxicitycomorbiditiesdrug interactionshyperlipidemiastatin safety

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Related Experiment Videos

Last Updated: Jan 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.5K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Area of Science:

  • Pharmacology
  • Oncology
  • Cardiovascular Medicine

Background:

  • Cardiovascular disease (CVD) and cancer share risk factors.
  • Statins, used for CVD prevention, may interact with cancer treatments.
  • Drug-drug interactions (DDIs) between statins and oncology agents are a clinical concern.

Purpose of the Study:

  • To quantify and characterize DDIs between commonly prescribed statins and recent oncology agents.
  • To evaluate statin prescribing trends in diverse cancer patient populations.

Main Methods:

  • Screened FDA oncology drug approvals (June 2019-June 2024) for interactions with 5 statins using UpToDate Lexidrug.
  • Classified interaction severity into 5 risk levels.
  • Analyzed statin prescribing rates via a scoping review of 20 PubMed-indexed observational studies.

Main Results:

  • 33% of 138 oncology agents showed DDIs with statins; simvastatin had the highest interaction rate.
  • Most interactions (88%) were level C (monitoring required); level X (contraindicated) interactions occurred with adagrasib, tucatinib, and asciminib.
  • Statin use was highest in prostate (53%) and lung (32%) cancers, and lowest in liver (8%) and breast (10%) cancers.

Conclusions:

  • Statin-oncology agent DDIs are frequent but rarely contraindicated, emphasizing monitoring.
  • Statin utilization patterns differ significantly across cancer types.
  • Individualized risk-benefit assessments are crucial for guiding statin therapy in cancer patients, considering prognosis, CVD risk, and potential DDIs.